Drug Profile
Research programme: chemokine receptor antagonists - Alliance Discovery
Alternative Names: JMS-17-2Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Alliance Discovery
- Class Antineoplastics; Small molecules
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 10 Aug 2016 Preclinical trials in Cancer in USA (unspecified route)